Wedbush Upgrades Sarepta Therapeutics Inc to Outperform with Price Target $36.00

Brokerage firm Wedbush Upgrades its rating on Sarepta Therapeutics Inc(NASDAQ:SRPT). In a research note issued to the investors, the brokerage major Raises the price-target to $36.00 per share. The shares have been rated Outperform. Previously, the analysts had a Neutral rating on the shares. The rating by Wedbush was issued on Jun 7, 2016.

In a different note, On May 2, 2016, Oppenheimer said it Upgrades its rating on Sarepta Therapeutics Inc. The shares have been rated ‘Outperform’ by the firm. On May 2, 2016, Leerink Swann said it Downgrades its rating on Sarepta Therapeutics Inc. In the research note, the firm Lowers the price-target to $13.00 per share. The shares have been rated ‘Underperform’ by the firm. On Apr 29, 2016, Jefferies said it Downgrades its rating on Sarepta Therapeutics Inc. The shares have been rated ‘Underperform’ by the firm. On Apr 26, 2016, Oppenheimer said it Downgrades its rating on Sarepta Therapeutics Inc. The shares have been rated ‘Perform’ by the firm. On Apr 26, 2016, SunTrust Robinson Humphrey said it Downgrades its rating on Sarepta Therapeutics Inc. In the research note, the firm Lowers the price-target to $14.00 per share. The shares have been rated ‘Reduce’ by the firm. On Apr 26, 2016, Jefferies said it Maintains its rating on Sarepta Therapeutics Inc. In the research note, the firm Lowers the price-target to $14.00 per share. The shares have been rated ‘Hold’ by the firm.

Sarepta Therapeutics Inc (SRPT) shares turned negative on Fridays trading session with the shares closing down -1.04 points or -4.95% at a volume of 37,56,176. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $20.75. The peak price level was also seen at $20.75 while the days lowest was $19.67. Finally the shares closed at $19.95. The 52-week high of the shares is $41.97 while the 52-week low is $8. According to the latest information available, the market cap of the company is $913 M.

Sarepta Therapeutics Inc(SRPT) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $0.00. Analysts had an estimated revenue of $450.00K. Earnings per share were $-1.15. Analysts had estimated an EPS of $-1.30.

Several Insider Transactions has been reported to the SEC. On Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price.Also, On Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price.On Mar 16, 2016, Richard Barry (director) purchased 75,000 shares at $15.66 per share price, according to the Form-4 filing with the securities and exchange commission.

Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *